Pharmacolog signs agreement with B. Braun S.A.

Pharmacolog has entered into an agreement with B. Braun Medical S.A Spain concerning exclusive distribution of DrugLog® on the Spanish market. The agreement also considers the future integration of DrugLog® with one of the company’s software Oncology technologies.

Braun Medical S.A. Spain is a company within the B. Braun Group engaged, among other activities, in the product development in the field of Injectable Drug Delivery. The area includes developing new solutions for managing the entire process of chemotherapy with cytotoxic drugs, from prescription to patient infusion. The agreement signed between Pharmacolog and B. Braun Medical Spain means that B. Braun acts as an exclusive distributor of DrugLog on the Spanish market and that the companies jointly work together to develop new and groundbreaking systems and solutions for safer and more efficient drug administration.

Mats Högberg CEO of Pharmacolog comments: “We are very pleased to start a collaboration with one of the world’s leading medical technology companies. B. Braun Medical S.A. Spain is fully involved in the development of infusion therapy and are experts in this field. They will now represent Pharmacolog in the Spanish market, while at the same time investigating the possibilities of working in conjunction with the development of new solutions to manage the entire workflow of cellular drugs, from prescription to patient infusion.”

Pharmacolog kallar till bolagsstämma

Aktieägarna i Pharmacolog i Uppsala AB (publ), 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.

Anmälan m.m.

Aktieägare som önskar delta vid årsstämman skall:

–    dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och

–    dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till

Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (ell...

Continued negotiations with international MedTech Group

In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.

The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quar...

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...

Study in Lille completed

The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.

The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially result...